Developing Medical Innovation

We develop new technologies from the NHS and beyond to improve patient care

Realising Potential

Medovate is a dynamic medical device company dedicated to the development and commercialisation of innovative medical technologies created within the NHS and beyond.

Medovate provides technical, management and financial support to develop medical devices through clinical trials, regulatory approval and market launch, in order to improve patient safety and healthcare delivery.

Our current pipeline of novel medical technologies is focussed on anaesthesia, airway, critical care and surgery.

** COVID-19 pandemic: Medovate remains fully operational during this time. Team members are fully able to work from home and can be contacted via phone and e-mail. Please see post in 'News' for full details.**

Read More
operation-540597_1920_resized.jpg

Latest News

Keep up to date with Medovate News & Events

News

Medovate signs exclusive agreement with Vygon to distribute regional anaesthesia device

19th October, 2020

Medovate and Vygon Group announce that they have signed an exclusive deal to distribute SAFIRA® (SAFer Injection for Regional Anaesthesia) across 60 countries. Vygon will start a phased launch of SAFIRA in Europe at the end of 2020, with other global markets to follow.

News

Medovate’s SAFIRA® featured in Journal of Anaesthesia Practice

28th September, 2020

Medovate’s game-changing SAFIRA® (SAFer Injection for Regional Anesthesia) has been featured in the Journal of Anaesthesia Practice. The article, written by Dr Stewart Southey, looks at how the COVID-19 pandemic has challenged the very nature of anaesthesia services, and the need for increased attention on patient safety in regional anaesthesia.

News

Medovate’s game-changing anaesthesia device SAFIRA® receives European CE regulatory approval

15th September, 2020

Medovate – a pioneering medical device development company specialising in anaesthesia, airway management, critical care, and surgery – announced it has received CE Mark Approval for its game-changing medical device SAFIRA® (SAFer Injection for Regional Anaesthesia).